{
    "paper_id": "c43cca482a991dd6315c3d9735e80ae16120b044",
    "metadata": {
        "title": "Journal Pre-proof Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)- Associated Interstitial Lung Disease During the COVID-19 Pandemic Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Associated Interstitial Lung Disease During the COVID-19 Pandemic",
        "authors": [
            {
                "first": "Hsu-Liang",
                "middle": [],
                "last": "Chang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Kaohsiung Medical University",
                    "location": {
                        "settlement": "Kaohsiung",
                        "country": "Taiwan"
                    }
                },
                "email": ""
            },
            {
                "first": "Yen-Hsu",
                "middle": [],
                "last": "Chen",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Kaohsiung Medical University",
                    "location": {
                        "settlement": "Kaohsiung",
                        "country": "Taiwan"
                    }
                },
                "email": ""
            },
            {
                "first": "Chih-Jen",
                "middle": [],
                "last": "Yang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Kaohsiung Medical University",
                    "location": {
                        "settlement": "Kaohsiung",
                        "country": "Taiwan"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-associated interstitial lung disease (ILD) and COVID-19 infection share similar clinical and imaging findings. How to distinguish between the two diseases is a crucial issue during the current COVID-19 pandemic.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor:"
        },
        {
            "text": "Lung cancer is the leading cause of death worldwide. TKIs targeting EGFR have been shown to improve progression-free survival in patients with non-small cell lung cancer harboring sensitive EGFR mutations. The most serious adverse drug reaction in patients receiving EGFR TKIs is ILD, with an incidence in Japan of 1.6-4.3% and 0.3-1% worldwide 1 . The median interval to onset is 1-2 months from the first dose, and the mortality rate can reach 13-50% 1 . Chest CT findings of EGFR TKI-associated ILD can be divided into four patterns 2 : nonspecific areas with ground glass opacity (GGO), multifocal areas of airspace consolidations, patchy distribution of GGO accompanied by interlobar septal thickening, and extensive bilateral GGO or airspace consolidations with traction bronchiectasis. The latter has the worst prognosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor:"
        },
        {
            "text": "Symptoms of EGFR TKI-associated ILD are non-specific, with the most common being dyspnea (94.3%), fever (51.4%), cough (20%) and 5.7% of patients are asymptomatic 1 .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor:"
        },
        {
            "text": "EGFR TKI-associated ILD is diagnosed essentially by the exclusion of other diseases. Taken together, it is very difficult to distinguish between COVID-19 infection and EGFR TKI-associated ILD with clinical and imaging presentations. For an early diagnosis, rapid tests for SARS-CoV2 are necessary, such as RT-PCR, isothermal amplification assays or serology tests to differentiate COVID-19 infection from EGFR TKI-associated ILD, especially in the first 1-2 months after starting EGFR TKI therapy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Dear Editor:"
        },
        {
            "text": "In addition, standard treatment for EGFR TKI-associated ILD is to discontinue TKIs and start high-dose steroids immediately, however high-dose steroid treatment has been reported to be harmful for patients with COVID-19 infection 5 .",
            "cite_spans": [
                {
                    "start": 230,
                    "end": 231,
                    "text": "5",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Dear Editor:"
        },
        {
            "text": "In Table 1 , we summarize the differences between EGFR TKI-associated ILD and COVID-19 infection. Table 1 . The differences between EGFR TKI-associated interstitial lung disease (ILD) and COVID-19",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 3,
                    "end": 10,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 98,
                    "end": 105,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "Dear Editor:"
        },
        {
            "text": "infection. myalgia/arthralgia 10-15%, headaches 10-36%, sore throat 10-15%, chills 10-12%.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Legends"
        },
        {
            "text": "Early detection and discontinue EGFR TKI and start high-dose steroids as soon as possible.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment"
        },
        {
            "text": "No FDA-approved drugs as yet Steroids may be harmful 5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "R"
                    ],
                    "last": "Shah",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Drug Saf",
            "volume": "39",
            "issn": "",
            "pages": "1073--1091",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Endo",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Johkoh",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Kimura",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Lung Cancer",
            "volume": "52",
            "issn": "",
            "pages": "135--140",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients",
            "authors": [
                {
                    "first": "Hyf",
                    "middle": [],
                    "last": "Wong",
                    "suffix": ""
                },
                {
                    "first": "Hys",
                    "middle": [],
                    "last": "Lam",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "H"
                    ],
                    "last": "Fong",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Radiology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Eur Radiol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Russell",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "E"
                    ],
                    "last": "Millar",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "K"
                    ],
                    "last": "Baillie",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "473--475",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Early diagnosis, discontinuing EGFR TKIs and starting high-dose steroid treatment as soon as possible is recommended.At the time of writing, 2,927,523 people have been confirmed with COVID-19 infection and 202,107 people have died worldwide, with a mortality rate of 6.9%. The median incubation period of SARS-CoV2 is 5.1 days, with 97.5% of patients becoming symptomatic within 11.5 days. Chest x ray (CXR) is most commonly used to detect lesions in patients with COVID-19 infection in most countries, however only 33.3-69% of COVID-19-infected patients have abnormalities on CXR 3 . In addition, the severity on CXR peaks at 10-12 days from symptom onset. Chest CT for patients with COVID-19 infection is highly sensitive, and the cardinal hallmarks of COVID-19 on chest CT are bilateral distribution of GGO with or without consolidation in posterior and peripheral lungs, and the most common picture on chest CT includes GGO 14-98%, consolidation 2-64%; GGO with consolidation 19-59%; and interlobular septum thickening 1-75% 4 . The most common symptoms of patients with COVID-19include fever (85-90%), cough (65-70%), fatigue (35-40%), sputum production (30-35%), shortness of breath (15-20%), myalgia/arthralgia (10-15%), headaches (10-36%), sore throat (10-15%), and chills (10-12%).",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "The differences between EGFR TKI-associated interstitial lung disease (ILD) and COVID-19DiagnosisDiagnosis of EGFR TKI-associated interstitial pneumonitis is made essentiallyby exclusion of others RT-PCR, isothermal amplification assays, serology tests Symptoms Non-specific, dyspnea 94.3%, fever 51.4%, cough 20%, asymptomatic 5.7% Fever 85-90%, cough 65-70%, fatigue 35-40%, sputum production 30-35%, shortness of breath 15-20%",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}